collection
MENU ▼
Read by QxMD icon Read
search

Lung cancer

shared collection
201 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28431712/salvage-operation-in-case-of-oligometastatic-disease
#1
Nicolas Duchateau, Erik Van Bouwel, Paul E Van Schil
In general, prognosis of stage IV non-small cell lung cancer is poor, and treatment is mostly palliative. However, oligometastatic disease is currently recognized as a specific entity with a better prognosis. We report a patient where combined chemoradiotherapy and salvage surgery led to extraordinary long-term survival.
May 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28433219/importance-of-ground-glass-opacity-component-in-clinical-stage-ia-radiologic-invasive-lung-cancer
#2
Aritoshi Hattori, Takeshi Matsunaga, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki
BACKGROUND: We evaluated the clinical significance of the presence of a ground glass opacity (GGO) component in clinical stage IA radiologic invasive non-small cell lung cancer (NSCLC). METHODS: We reviewed 497 surgically resected clinical stage IA radiologic invasive NSCLCs, which were then classified into two groups based on consolidation tumor ratio (CTR), that is part-solid (0.5 ≤ CTR < 1.0, n = 177) and pure-solid (CTR = 1.0, n = 320). The part-solid tumors were subdivided into GGO-predominant (0...
April 19, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28433225/adjuvant-chemotherapy-is-associated-with-improved-survival-in-locally-invasive-node-negative-non-small-cell-lung-cancer
#3
Usman Ahmad, Traves D Crabtree, Aalok P Patel, Daniel Morgensztern, Cliff G Robinson, A Sasha Krupnick, Daniel Kreisel, David R Jones, G Alexander Patterson, Bryan F Meyers, Varun Puri
BACKGROUND: The objectives of this study are to explore factors that are associated with use of adjuvant chemotherapy and to evaluate its impact on overall survival in node-negative patients who undergo lung and chest wall resection for non-small cell lung cancer (NSCLC). METHODS: Patients who underwent concomitant lung and chest wall resection for NSCLC were abstracted from the National Cancer Database. Clinical, pathologic, treatment, and follow-up data were obtained...
April 19, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28477635/pulmonary-toxicities-from-checkpoint-immunotherapy-for-malignancy
#4
REVIEW
Jennifer D Possick
Checkpoint immunotherapy with agents targeting PD-1 and CTLA-4 has transformed the landscape of oncologic therapy. Immune-related adverse events (IRAEs), including significant pulmonary toxicities, have been observed in patients treated with these agents. The incidence, timing, clinical features, and outcomes of pulmonary IRAEs are quite variable, emphasizing the importance for clinical vigilance as these therapies become more ubiquitous in the treatment of a spectrum of malignancies. Outcomes are generally favorable when toxicity is recognized early and treated promptly...
June 2017: Clinics in Chest Medicine
https://www.readbyqxmd.com/read/28484151/surgical-treatment-for-pulmonary-metastasis-of-head-and-neck-cancer-study-of-58-cases
#5
Yuki Nakajima, Yoshihito Iijima, Hiroyasu Kinoshita, Hirohiko Akiyama, Takeshi Beppu, Hidetaka Uramoto, Tomomi Hirata
PURPOSE: Although the number of surgeries performed for pulmonary metastasis of head and neck cancer has been increasing, there have been few reports of the surgical effectiveness. We collected the data of surgeries performed in our facility in order to discuss the surgical performance and indication. METHODS: We retrospectively examined the prognosis and predictors for 58 patients with pulmonary metastasis of head and neck cancer who underwent a surgery in our facility during the 15-year period, from January 2000 to December 2015...
May 9, 2017: Annals of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28467720/second-line-therapy-of-squamous-non-small-cell-lung-cancer-an-evolving-landscape
#6
Chiara Lazzari, Niki Karachaliou, Vanesa Gregorc, Alessandra Bulotta, Maria Gonzalez-Cao, Alberto Verlicchi, Giuseppe Altavilla, Rafael Rosell, Mariacarmela Santarpia
The treatment of lung cancer has radically changed over the last few years. The discovery of druggable oncogenic alterations and the introduction of immunotherapy have provided lung cancer patients with the possibility of more efficient and less toxic therapeutic alternatives than chemotherapy. In the case of lung squamous cell carcinoma (LSCC), the treatment progress is slower than adenocarcinoma, for which several targeted agents have been already approved. The standard first-line therapy for LSCC, in most sites of the world, is platinum-based chemotherapy...
May 15, 2017: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/28301208/measures-to-prevent-air-embolism-in-transthoracic-biopsy-of-the-lung
#7
Bernhard Glodny, Elisabeth Schönherr, Martin C Freund, Melanie Haslauer, Johannes Petersen, Alexander Loizides, Astrid E Grams, Florian Augustin, Franz J Wiedermann, Rafael Rehwald
OBJECTIVE: Systemic air embolism (AE) is a rare but feared complication of transthoracic biopsy with potentially fatal consequences. The aim of the study was to assess the effect of patient positioning during transthoracic biopsy on preventing systemic AE. MATERIALS AND METHODS: We compared a historical control group of 610 patients (group 1) who underwent transthoracic biopsy before the implementation of measures to prevent systemic AE during transthoracic biopsy and a group of 1268 patients (group 2) who underwent biopsy after the measures were implemented...
May 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28197215/pleural-procedures-in-the-management-of-malignant-effusions
#8
REVIEW
Lucía Ferreiro, Juan Suárez-Antelo, Luis Valdés
Malignant pleural effusion (MPE) is common in clinical practice, and despite the existence of studies to guide clinical decisions, it often poses diagnostic and therapeutic dilemmas. Once it is diagnosed, median survival does not usually exceed 6 months. The management of these patients focuses on symptom relief since no treatments have been shown to increase survival to date. Conversely, poor management can shorten survival. The approach must be multidisciplinary and allow for individualized care. Initial diagnostic procedures should be minimally invasive and, according to the results and other factors, procedures of increasing complexity will be selecting...
January 2017: Annals of Thoracic Medicine
https://www.readbyqxmd.com/read/28049169/management-of-stage-i-and-ii-nonsmall-cell-lung-cancer
#9
Fiona McDonald, Michèle De Waele, Lizza E L Hendriks, Corinne Faivre-Finn, Anne-Marie C Dingemans, Paul E Van Schil
The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome. Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard...
January 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/27927060/new-data-on-clinical-decisions-in-nsclc-patients-with-uncommon-egfr-mutations
#10
Ting-Hui Wu, Emily Han-Chung Hsiue, Jih-Hsiang Lee, Chia-Chi Lin, James Chih-Hsin Yang
Non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor (EGFR) mutations together account for approximately 10% of all EGFR mutations. The most common of which being G719X, S768I, L861Q, and exon 20 insertions. The clinical significance, particularly their response to EGFR tyrosine kinase inhibitors (TKIs) is largely unclear. Previous data is limited to a small fraction of patients in prospective studies and retrospective series. Recently, a combined analysis of patients with uncommon EGFR mutations in the Lux-Lung 2, Lux-Lung 3, Lux-Lung 6 trials provide new perspectives of uncommon EGFR mutations...
January 2017: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/28005439/early-lung-cancer-detection-by-low-dose-ct-screening-therapeutic-implications
#11
Marjolein A Heuvelmans, Harry J M Groen, Matthijs Oudkerk
Lung cancer screening by low-dose chest computed tomography is currently implemented in the U.S. After implementation of screening, a stage shift may be observed from around 15% stage I non-small cell lung cancers (NSCLCs) in routine clinical practice to up to 70% in screening patients. This indicates a move in treatment options from advanced to early lung cancers, especially in those with small suspected intrapulmonary nodules. Areas covered: We have reviewed the current status of lung cancer screening from the different randomized controlled lung cancer screening studies and the clinical evidence so far for both surgical and non-surgical treatment options for (screen-detected) stage I NSCLC...
December 30, 2016: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/28152323/chemotherapy-and-intercalated-gefitinib-or-erlotinib-in-the-treatment-of-advanced-non-small-cell-lung-cancer
#12
Antonio Rossi, Anna La Salvia, Massimo Di Maio
Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC...
March 2017: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/28212155/molecular-markers-in-lung-cancer-role-of-ebus
#13
Semra Bilaçeroğlu
PURPOSE OF REVIEW: As demonstrated by the recent therapeutic advances in nonsmall cell lung cancer (NSCLC), a personalized approach can considerably reduce its mortality. RECENT FINDINGS: Molecular tests identifying genetic mutations in NSCLC have led to a shift towards more effective and personalized therapies targeted to these alterations. Adequate tissue is required for diagnosing, subcharacterizing, and genotyping NSCLC by morphological, immunohistochemical, and molecular techniques...
May 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/28131635/effect-of-combined-therapy-inhibiting-egfr-and-vegfr-pathways-in-non-small-cell-lung-cancer-on-progression-free-and-overall-survival
#14
Tao Jiang, Meng Qiao, Fei Zhou, Shengxiang Ren, Chunxia Su, Caicun Zhou
BACKGROUND: To investigate the effect of combined epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway inhibitors on progression-free survival (PFS) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: We included 15 randomized clinical trials that had compared the combination of EGFR tyrosine kinase inhibitors and anti-VEGF/VEGFR therapy with different control groups...
December 29, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28162945/postoperative-adjuvant-systemic-therapy-in-completely-resected-non-small-cell-lung-cancer-a-systematic-review
#15
REVIEW
Penelope Bradbury, Duvaraga Sivajohanathan, Adrien Chan, Swati Kulkarni, Yee Ung, Peter M Ellis
The purpose of the present review was to determine whether the use of postoperative adjuvant systemic therapy in patients with completely resected non-small-cell lung cancer (NSCLC) improves survival. Cancer Care Ontario's Program in Evidence-Based Care reviewed the evidence to update previously published recommendations for patients with completely resected NSCLC. Relevant studies were identified from a systematic MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews search of studies published from 2010 to 2016...
July 12, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28188100/the-use-of-antiangiogenic-agents-for-lung-cancer-in-elderly-patients-an-expert-panel-discussion-synopsis
#16
Mark A Socinski, Jamie E Chaft, Benjamin Levy, Gregory J Riely, Corey J Langer, Roman Perez-Soler, Deborah L Middleton, Linda Gracie-King, Laura M Healy
No abstract text is available yet for this article.
January 5, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28188101/antiangiogenic-therapy-in-advanced-non-small-cell-lung-cancer-a-meta-analysis-of-phase-iii-randomized-trials
#17
REVIEW
Jacques Raphael, Kelvin Chan, Safiya Karim, Robert Kerbel, Henry Lam, Keemo Delos Santos, Ronak Saluja, Sunil Verma
We conducted a meta-analysis to evaluate the efficacy of adding any antiangiogenic therapy (AT) to the standard of care in advanced non-small-cell lung cancer (NSCLC). The electronic databases Ovid PubMed, Cochrane Central Register of Controlled Trials, and Embase were searched to identify eligible trials. We included all phase III randomized trials with any line and type of treatment, histology. and AT dose. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and pooled odds ratio (OR) for overall response rates (RR) were calculated...
January 12, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28108179/symptomatic-treatment-of-cough-among-adult-patients-with-lung-cancer-chest-guideline-and-expert-panel-report
#18
Alex Molassiotis, Jaclyn A Smith, Peter Mazzone, Fiona Blackhall, Richard S Irwin
BACKGROUND: Cough among patients with lung cancer is a common but often undertreated symptom. We used a 2015 Cochrane systematic review, among other sources of evidence, to update the recommendations and suggestions of the American College of Chest Physicians (CHEST) 2006 guideline on this topic. METHODS: The CHEST methodologic guidelines and the Grading of Recommendations, Assessment, Development, and Evaluation framework were used. The Expert Cough Panel based their recommendations on data from the Cochrane systematic review on the topic, uncontrolled studies, case studies, and the clinical context...
April 2017: Chest
https://www.readbyqxmd.com/read/28074083/management-of-malignant-pleural-effusion-with-asept%C3%A2-pleural-catheter-quality-of-life-feasibility-and-patient-satisfaction
#19
Inderdeep Dhaliwal, Masoud Mahdavian, Shabnam Asghari, Benson Chun To Wong, Rosalie Labelle, Kayvan Amjadi
Objective. The PleurX® IPC system has been used extensively in the past. Over time, management of MPE with the PleurX system can be costly. The new ASEPT pleural catheter, through advantages in design, may ultimately show cost savings. The primary outcome of this study was to evaluate safety and efficacy of the ASEPT system. Method. This single centre, prospective study enrolled 50 patients with MPE, who were followed for as long as they were alive with a catheter. Quality of Life (QoL) was assessed before, at 2 weeks, and 6 weeks after ASEPT catheter insertion using the EORTC QLQ-C30 and LC13 questionnaires...
2016: Canadian Respiratory Journal: Journal of the Canadian Thoracic Society
https://www.readbyqxmd.com/read/28026127/well-differentiated-bronchial-neuroendocrine-tumors-clinical-management-and-outcomes-in-105-patients
#20
Marinos Pericleous, Anna Karpathakis, Christos Toumpanakis, Heather Lumgair, Jonathan Reiner, Laura Marelli, Christina Thirlwell, Martyn E Caplin
INTRODUCTION: Bronchial neuroendocrine tumors (NETs) are rare tumors representing approximately 20%-30% of all neuroendocrine tumors and 2%-3% of all adult lung cancers. Here, they present a large case series of well-differentiated bronchial NETs with the aim of investigating the behavior of these tumors and long-term outcomes. METHODS: A retrospective review was performed of 105 patients with bronchial NETs managed in a tertiary referral center in the period between January 1998 and January 2012...
December 27, 2016: Clinical Respiratory Journal
label_collection
label_collection
5851
1
2
2017-01-17 22:02:56
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"